Approximately one in four patients died, deteriorated to a higher shock stage, or were transferred for a higher level of care ...

Cardiogenic shock happens when the heart suddenly can’t pump enough blood to meet the body’s needs. This leads to a drop in ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced its strategy to secure 7.5 years of U.S. exclusivity ...

Despite substantial advancements in the management of cardiogenic shock, mortality rates remain greater than 40%. Trials have ...

The outcomes of the SHOCK trial led to a ACC/AHA class 1A recommendation for an early invasive strategy in acute MI complicated by cardiogenic ... ACC/AHA/SCAI 2005 guideline update for ...

Windtree Therapeutics, Inc. announced that it has received guidance from intellectual property and FDA experts regarding a potential strategy for its drug istaroxime, which targets cardiogenic shock.

In one of the largest studies of early cardiogenic shock (CS) patients, where blood flow is still functioning to vital organs ...

If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until ...

In one of the largest studies of early cardiogenic shock (CS) patients, where blood flow is still functioning to vital organs, researchers demonstrated that 26% experienced worse outcomes, including ...

Initiated enrollment in the global SEISMiC C trial evaluating istaroxime in SCAI Stage C cardiogenic shock—a more severely ... bitartrate), a first-in-class hormone-free, on-demand prescription ...

A leading interventional cardiologist, he is internationally recognized for his work in hypertrophic cardiomyopathy and cardiogenic shock, and is the lead author of the SCAI SHOCK Classification.

In one of the largest studies of early cardiogenic shock (CS) patients ... Society for Cardiovascular Angiography & Interventions (SCAI) 2025 Scientific Sessions. CS is a life-threatening ...